FDA Approves Prevnar 20 Vaccine to Prevent Invasive Pneumococcal Disease in Children 6 Weeks Through 17 Years
Prevnar 20 is a next-generation pneumococcal conjugate vaccine that includes capsular polysaccharide conjugates for the 13 serotypes already included in Prevnar 13.
United States Baylor College Of Medicine Sheldon Kaplan Annaliesa Anderson Infectious Disease Service Department Of Pediatrics
Source: pharmacytimes.com